These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8955848)

  • 1. Therapeutic potential of anti-HIV immunotoxins.
    Pincus SH
    Antiviral Res; 1996 Dec; 33(1):1-9. PubMed ID: 8955848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo testing of anti-HIV immunotoxins.
    Pincus SH; Marcotte TK; Forsyth BM; Fang H
    Methods Mol Biol; 2001; 166():277-94. PubMed ID: 11217373
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus.
    Davey RT; Boenning CM; Herpin BR; Batts DH; Metcalf JA; Wathen L; Cox SR; Polis MA; Kovacs JA; Falloon J
    J Infect Dis; 1994 Nov; 170(5):1180-8. PubMed ID: 7963711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
    Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC
    J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CD4-derivatives therapy of HIV carriers].
    Mizukami T; Mitsuya H
    Nihon Rinsho; 1993 Sep; 51 Suppl():327-33. PubMed ID: 8271399
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
    J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.
    Ramachandran RV; Katzenstein DA; Wood R; Batts DH; Merigan TC
    J Infect Dis; 1994 Oct; 170(4):1009-13. PubMed ID: 7930696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insertion of constant region domains of human IgG1 into CD4-PE40 increases its plasma half-life.
    Batra JK; Kasturi S; Gallo MG; Voorman RL; Maio SM; Chaudhary VK; Pastan I
    Mol Immunol; 1993 Mar; 30(4):379-86. PubMed ID: 8455638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.
    Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1091-6. PubMed ID: 8312052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons.
    Saavedra-Lozano J; McCoig C; Xu J; Cao Y; Keiser P; Ghetie V; Siliciano RF; Siliciano JD; Picker LJ; Ramilo O; Vitetta ES
    J Infect Dis; 2002 Feb; 185(3):306-14. PubMed ID: 11807712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160.
    Pincus SH; Wehrly K; Cole R; Fang H; Lewis GK; McClure J; Conley AJ; Wahren B; Posner MR; Notkins AL; Tilley SA; Pinter A; Eiden L; Teintze M; Dorward D; Tolstikov VV
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):1041-51. PubMed ID: 8827220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques.
    Kennedy PE; Bera TK; Wang QC; Gallo M; Wagner W; Lewis MG; Berger EA; Pastan I
    J Leukoc Biol; 2006 Nov; 80(5):1175-82. PubMed ID: 16923920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 toxin holds promise as treatment for HIV infection.
    Am Fam Physician; 1988 Nov; 38(5):355-6. PubMed ID: 3263790
    [No Abstract]   [Full Text] [Related]  

  • 15. Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.
    Pincus SH; McClure J
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):332-6. PubMed ID: 8419938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis.
    Rose JW; Lorberboum-Galski H; Fitzgerald D; McCarron R; Hill KE; Townsend JJ; Pastan I
    J Neuroimmunol; 1991 Jun; 32(3):209-17. PubMed ID: 1709644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
    FitzGerald DJ; Wayne AS; Kreitman RJ; Pastan I
    Cancer Res; 2011 Oct; 71(20):6300-9. PubMed ID: 21998010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.
    Berger EA; Moss B; Pastan I
    Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11511-3. PubMed ID: 9751696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4.
    Martín-Serrano J; Folgueira L; Laín de Lera T; Pedraza MA; Lemichez E; Sánchez-Palomino S; Noriega AR; Boquet P; Alcamí J
    AIDS; 1998 May; 12(8):859-63. PubMed ID: 9631138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.